Inarigivir soproxil

Cat. No.: HY-109035
CAS No.: 942123-43-5
Molecular Formula: C₂₅H₃₄N₇O₁₃PS
Molecular Weight: 703.62
Target: HCV
Pathway: Anti-infection
Storage: Powder
-20°C 3 years
4°C 2 years
In solvent
-80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro
DMSO : ≥ 102 mg/mL (144.96 mM)*
*“≥” means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>Mass</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>1 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td>1 mM</td>
<td>1.4212 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.2842 mL</td>
<td>1.4212 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.1421 mL</td>
<td>0.7106 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC₅₀ values of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

IC₅₀ & Target
EC₅₀: 2.2/1.0 μM (HCV 1a/1b)\(^{[1]}\).

In Vitro
Inarigivir soproxil (SB 9200) is an oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV). Inarigivir soproxil is shown to inhibit HCV replication and the range of inhibition is comparable between genotypes 1a and 1b. Inarigivir soproxil demonstrates pan-genotypic antiviral activity against HCV. Inarigivir soproxil is active against DAA-resistant HCV variants\(^{[1]}\).